uniQure N.V. (NASDAQ:QURE) Short Interest Up 33.8% in December

uniQure N.V. (NASDAQ:QURE) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 11,996,689 shares, a growth of 33.8% from the December 15th total of 8,966,485 shares. Based on an average trading volume of 2,755,072 shares, the short-interest ratio is currently 4.4 days. Currently, 20.2% of the shares of the company are sold short. Currently, 20.2% of the shares of the company are sold short. Based on an average trading volume of 2,755,072 shares, the short-interest ratio is currently 4.4 days.

Analysts Set New Price Targets

Several brokerages have recently issued reports on QURE. Mizuho reduced their price target on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, December 8th. Stifel Nicolaus cut their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Chardan Capital restated a “buy” rating and issued a $53.00 target price on shares of uniQure in a research report on Thursday, December 4th. Wells Fargo & Company cut their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Finally, The Goldman Sachs Group reduced their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.82.

uniQure Stock Performance

QURE opened at $22.84 on Friday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.42 billion, a PE ratio of -5.20 and a beta of 0.68. The business has a fifty day simple moving average of $24.77 and a 200-day simple moving average of $27.72. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, equities analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Transactions at uniQure

In other uniQure news, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the transaction, the director directly owned 40,145 shares in the company, valued at $1,094,352.70. The trade was a 43.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $620,119.26. This trade represents a 65.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 102,247 shares of company stock worth $2,839,298 in the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently bought and sold shares of QURE. Woodline Partners LP lifted its position in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in uniQure in the 2nd quarter worth approximately $117,000. Aberdeen Group plc boosted its stake in shares of uniQure by 24.2% during the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after buying an additional 535,163 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of uniQure during the 2nd quarter valued at $872,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of uniQure in the second quarter worth $151,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.